Sugi Predict

Sugi Predict / Compounds / SCHEMBL14033767

SCHEMBL14033767

SCHEMBL14033767

CCOC(=O)c1cnn2cc(Br)cnc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.55
▸ HPGD P15428 5/20 0.55
▸ KDM4E B2RXH2 6/20 0.54
▸ RAB9A P51151 5/20 0.54
▸ NPC1 O15118 4/20 0.54
▸ MAPT P10636 2/20 0.44
▸ KMT2A Q03164 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ CSNK1D P48730 1/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ POLB P06746 2/20 0.43
▸ HTT P42858 1/20 0.43
▸ RECQL P46063 1/20 0.43
▸ NFKB1 P19838 1/20 0.43
▸ NFKB2 Q00653 1/20 0.43
▸ RELA Q04206 1/20 0.43
▸ HSD17B10 Q99714 3/20 0.42
▸ LMNA P02545 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17781274 0.86 KDM4E (0.57) ALDH1A1HPGDKDM4ERAB9ANPC1
SCHEMBL23728550 0.84 ALDH1A1 (0.56) ALDH1A1HPGDKDM4ERAB9ANPC1
SCHEMBL23728526 0.84 ALDH1A1 (0.56) ALDH1A1HPGDKDM4ERAB9ANPC1
SCHEMBL23728472 0.83 ALDH1A1 (0.55) ALDH1A1HPGDKDM4ERAB9ANPC1
SCHEMBL309140 0.83 ALDH1A1 (0.55) ALDH1A1HPGDKDM4ERAB9ANPC1
SCHEMBL23728470 0.82 ALDH1A1 (0.54) ALDH1A1HPGDKDM4ERAB9ANPC1
SCHEMBL23728532 0.81 ALDH1A1 (0.55) ALDH1A1HPGDKDM4ERAB9ANPC1
SCHEMBL14033079 0.81 ALDH1A1 (0.53) ALDH1A1HPGDKDM4ERAB9ANPC1
SCHEMBL23728467 0.81 ALDH1A1 (0.53) ALDH1A1HPGDKDM4ERAB9ANPC1
SCHEMBL23728603 0.81 KDM4E (0.55) ALDH1A1HPGDKDM4ERAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4698517-A1 <SUP2/>? <SUB2/>?4?NOVEL COMPOUNDS AS ?? <NS1:SUB>7</NS1:SUB>?INHIBITORS Evotec International GmbH (DE) 2026-02-25 — — EP disclosed
WO-2024218058-A1 NOVEL COMPOUNDS AS α4β7 INHIBITORS EVOTEC INTERNATIONAL GMBH (DE) 2024-10-24 — — WO disclosed
US-20230286993-A1 CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE BOEHRINGER INGELHEIM INT (DE) 2023-09-14 — — US disclosed
US-20230286993-A1 CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE BOEHRINGER INGELHEIM INT (DE) 2023-09-14 — — US disclosed
US-11691977-B2 Cyclic ether derivatives of pyrazolo[1,5-A]pyrimidine-3-carboxyamide BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-07-04 — — US disclosed
US-11691977-B2 Cyclic ether derivatives of pyrazolo[1,5-A]pyrimidine-3-carboxyamide BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-07-04 — — US disclosed
US-20230122219-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-20 — — US disclosed
EP-4100004-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2022-12-14 — — EP disclosed
US-20220332718-A1 PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS GENENTECH, INC. (US) 2022-10-20 — — US disclosed
CN-108473498-B Pyrazolo [1,5a ] pyrimidine derivatives as IRAK4 modulators 豪夫迈·罗氏有限公司 2021-11-02 — — CN disclosed
US-20180134720-A1 CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE BOEHRINGER INGELHEIM INT (DE) 2018-05-17 — — US disclosed
US-20180134720-A1 CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE BOEHRINGER INGELHEIM INT (DE) 2018-05-17 — — US disclosed
WO-2017108723-A2 PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2017-06-29 — — WO disclosed
WO-2017108723-A2 PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2017-06-29 — — WO disclosed
WO-2017064082-A1 CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2017-04-20 — — WO disclosed
EP-3156405-A1 SPIROCYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE Boehringer Ingelheim International GmbH (DE) 2017-04-19 — — EP disclosed
US-20170101411-A1 CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2017-04-13 — — US disclosed
US-20170101411-A1 CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2017-04-13 — — US disclosed
US-20080255153-A1 New compounds BIOVITRUM AB (PUBL) (SE) 2008-10-16 — — US disclosed
US-20080255153-A1 New compounds BIOVITRUM AB (PUBL) (SE) 2008-10-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134720-A1 CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE CNP, PDE5A, PDE3A ALDH1A1 393/4885HPGD 301/4885KDM4E 458/4885
US-20230286993-A1 CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE CNP, PDE3A, PDE5A ALDH1A1 344/4885HPGD 416/4885KDM4E 431/4885
US-20170101411-A1 CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE CNP, PDE5A, PDE3A ALDH1A1 393/4885HPGD 301/4885KDM4E 458/4885
US-20230122219-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 ALDH1A1 2776/4885HPGD 3843/4885KDM4E 190/4885
US-11691977-B2 Cyclic ether derivatives of pyrazolo[1,5-A]pyrimidine-3-carboxyamide CNP, PDE5A, PDE3A ALDH1A1 393/4885HPGD 301/4885KDM4E 458/4885
US-20080255153-A1 New compounds SCD, SCD5, FADS2 ALDH1A1 1498/4885HPGD 364/4885KDM4E 1192/4885
US-20220332718-A1 PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS IRAK1, IRAK4, IRAK2 ALDH1A1 1115/4885HPGD 3802/4885KDM4E 662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.